• Gator will integrate one of Monod’s AI-designed NovoBody™ binding proteins into its industry-leading biolayer interferometry platform
• NovoBody™ binding proteins deliver superior performance, stability, and engineerability compared to traditional monoclonal antibodies

Seattle, WA & Palo Alto, CA — December 3, 2025 — Monod Bio, a leader in computational protein design, and Gator Bio, a pioneer in biolayer interferometry (BLI) technologies, today announced a partnership to integrate one of Monod’s proprietary AI-designed NovoBody™ protein binders into Gator’s biosensor platform. The collaboration combines Monod’s advanced AI-based protein design technology with Gator’s proven BLI platform to deliver next-generation biosensing capabilities.

Under the terms of the license agreement, Monod will supply NovoBody™ binding proteins to Gator Bio for use in a new biosensor product offering, one of the first to incorporate an AI-designed binding molecule. Gator Bio will oversee manufacturing, sales, and marketing of the biosensor, while Monod will receive upfront, supply, and royalty payments. The product launch is anticipated in the first half of 2026.

“Our collaboration with Gator Bio marks a significant milestone in the adoption of computationally designed binding proteins for biosensing applications, paving the way for broader use of NovoBody™ binding proteins across life science research and diagnostics,” said Daniel Silva Manzano, PhD, CEO of Monod Bio. “NovoBody™ binding proteins are computationally designed to deliver superior stability, manufacturability, and performance compared to traditional antibodies.”

“At Gator Bio, we are positioned at the intersection of AI innovation and experimental validation,” said Hong Tan, PhD, CEO of Gator Bio. “Our BLI instruments are a critical enabling technology for the AI protein design revolution, providing the real-time, label-free characterization that validates computationally designed molecules. By incorporating AI-designed NovoBody™ binding proteins into our biosensor portfolio, we are both advancing and benefiting from the AI transformation of biologics development.”

“This collaboration exemplifies our ‘Monod Inside’ business model,” said Carl Walkey, PhD, VP of Business Development at Monod Bio. “By integrating NovoBody™ binding proteins into leading industry platforms like Gator’s, we’re enabling partners to rapidly bring breakthrough products to market.”

About Monod Bio
Monod Bio is a Seattle-based biotechnology company and a spinout from the David Baker Lab at the University of Washington’s Institute for Protein Design, co-founded by Daniel Silva Manzano, Alfredo Quijano-Rubio, and David Baker. The company is a leader in de novo protein design to create novel protein binders and biosensors for research use only (RUO) and in vitro diagnostic (IVD) applications. Monod Bio’s proprietary AI platform enables the generation of novel proteins using in silico methods, including its NovoBody™ binders, to address unmet needs. Through its “Monod Inside” business model, Monod Bio partners with leading RUO and IVD organizations to bring next-generation products to market. For more information, visit http://monod.bio.

About Gator Bio

Gator Bio is a leading innovator in label-free biosensor technology, delivering high-performance analytical instruments for biomolecular interaction analysis. The company’s biolayer interferometry (BLI) platform serves as a critical validation technology for AI-driven protein design, providing researchers with powerful tools for real-time, quantitative characterization of next-generation biologics including computationally designed proteins and antibodies. For more information, visit gatorbio.com

Read at PR Newswire

Read at PR Newswire

View PDF

Gator Bio in partnership with GeneX India Bioscience is ready to serve the biotherapeutics research and manufacturing with next-gen biolayer interferometry

PALO ALTO, CA, UNITED STATES, April 18, 2023/EINPresswire.com/ — Gator Bio, the next-gen biolayer interferometry solutions company, has signed an agreement with GeneX India Bioscience Pvt Ltd, a Chennai-based distributor of innovative biomedical technology and products. The agreement will allow Gator Bio to expand its product offerings rapidly in India, a key region for Gator Bio’s global growth strategy.

Dr. Hong Tan, CEO of Gator Bio, said, “GeneX India has a track record of successfully introducing innovative products into market — as evidenced by its previous success in commercializing e.g., PEIpro, Double Dye Probe, FectoPRO etc. We look forward to working with the GeneX India team to bring the Gator platforms to users throughout the region, helping meet the demand for therapeutics development and manufacturing.”

“Gator BLI platforms and innovative biosensors are an important addition to GeneX India’s portfolio of Cell and Gene Therapy, Protein Biology products, and we are very excited about the possibilities the Gator shall give our customers in characterizing antibodies, AAVs and small molecule drugs,” said Mr. Felix Paul, CEO of GeneX India. “Access to this next-gen technology is key to the continued enablement of our biopharma and academia research customers in India. We are very excited about helping research and manufacturing community with the novel applications in gene therapy, immunotherapy, and lipid nanoparticle development.”

This partnership builds on Gator Bio’s commitment to providing high-quality BLI platforms globally. Gator Bio has recently entered into strategic partnerships with BMS Korea (Bio Medical Sciences), I&L Biosystems in Europe and Solve Scientific in Australia to provide sales and services to biotherapeutics and gene therapy companies. To learn more, please visit www.gatorbio.com.

About Gator Bio, Inc.
Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. The Gator next-gen biolayer interferometry (BLI) instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates and viral vectors, thus providing greater value in drug development and gene therapy applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China. For more information, please visit www.gatorbio.com

Subodh Nimkar
Gator Bio
+1 650-575-0827
email us here
Visit us on social media:
LinkedIn

Gator Bio launches Gator^® Pro, a high throughput and high performance next-gen BLI system, for biotherapeutics discovery

NEWS PROVIDED BY

Gator Bio

January 13, 2023, 20:46 GMT

Gator Bio aims to set a new industry standard for high throughput and accurate kinetics, epitope binning and quantitation for biotherapeutics discovery

PALO ALTO, CA, UNITED STATES, January 13, 2023 /EINPresswire.com/ — Today, Gator Bio, Inc. announced the launch of Gator^® Pro, a high throughput and high performance BLI system for biotherapeutics development. The system is capable of 32-channel high frequency data acquisition in parallel. Combined with the new Gator^® Screener software, the total solution delivers high-quality kinetics and epitope binning results in fraction of the time taken by traditional BLI and SPR systems.

The new high throughput Gator^® Pro expands the current next-gen BLI instrument portfolio that includes the 8-channel Gator^® Prime and Gator^® Plus systems.

“Antibody and protein therapeutics developers repeatedly ask for more efficient BLI solutions that combine throughput and performance. We believe Gator^® Pro addresses those needs. It can also complement SPR as a high throughput screening tool.” said Dr. Hong Tan, CEO of Gator Bio. “We are singularly focused on delivering easy, efficient and effective solutions that would enable scientists to develop biotherapeutics faster”.

Detailed info for the Gator^® Pro along with Gator Bio’s complete portfolio of next-gen BLI products can be found here.

About Gator Bio, Inc.
Gator Bio is a life sciences company providing analytical solutions to accelerate the development of therapeutics and diagnostics. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration, and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates and viral vector analytics, thus providing greater value in drug development and gene therapy applications, where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California. For more information, please visit www.gatorbio.com.

SOURCE Gator Bio, Inc.
Media and Investor Relations Contact:
Subodh Nimkar, Marketing Director
[email protected]
+1 650 575 0827

Subodh Nimkar
Gator Bio
+1 650-575-0827
email us here
Visit us on social media:
LinkedIn
YouTube

The AAV Titer and Empty/Full Ratio Determination in Upstream Crude Samples is Challenging. The New Gator Assays Offer a Practical Cost-Effective Solution

SAN JOSE, CA, UNITED STATES, November 15, 2022 /EINPresswire.com/ —

Today, Gator Bio, Inc. announced the launch of Gator^® AAV Ratio Kit, High Sensitivity AAV Kit and High Sensitivity AAV9 Kit for empty vs full ratio determination and titer, respectively. The assays run on FDA 21 CFR Part 11 compliant Gator^® Prime and Gator^® Plus biolayer interferometry (BLI) instruments. This is the only automated single platform solution in the market capable of accurate and easy determination of titer and empty vs full ratios at every stage of the AAV development and production.

The automated Gator^® High Sensitivity AAV Kit and High Sensitivity AAV9 Kit enable titer determination with the widest dynamic range for serotypes 1-10 in crude and purified samples. This kit fits into every stage of the AAV processing workflow, and the titer measurements correlate well with the gold standard methods.

The Gator^® AAV Ratio Kit is an innovative empty vs full method that easily and accurately measures ratios from 5-100% full capsids in crude and purified samples. Along with its simplicity, good AUC correlation, short time-to-result, and cost effectiveness, the Gator^® AAV Ratio Kit will fundamentally change how this analysis is routinely done.

Enabling gene therapy developers and manufacturers with cutting-edge tools is Gator Bio’s focus. “There are many challenges and new demands in AAV and other vector analytics, and we are dedicated to developing practical solutions leveraging Gator’s next-gen BLI and novel chemistry know-how” said Dr. Hong Tan, CEO of Gator Bio. “We are singularly focused on delivering easy, efficient and cost-effective solutions”.

Detailed info for the newly released solutions along with Gator Bio’s complete portfolio of products can be found at –https://www.gatorbio.com/applications/gene-therapy/

About Gator Bio, Inc.
Gator Bio is a life sciences company providing analytical solutions to accelerate the development of therapeutics and diagnostics. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration, and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates and viral vector analytics, thus providing greater value in drug development and gene therapy applications, where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California. For more information, please visit www.gatorbio.com.

SOURCE Gator Bio, Inc.
Media and Investor Relations Contact:
Subodh Nimkar, Marketing Director
[email protected]
+1 650 575 0827

Subodh Nimkar
Gator Bio
email us here
+1 6505750827
Visit us on social media:
LinkedIn

Gator Bio is proud to announce achievement of ISO 9001:2015 certification for our manufacturing facility, a globally recognized certification of quality management system standards.

This further communicates Gator Bio’s commitment to develop processes ensuring consistency, reliability, and accountability across our business operations. By achieving this level of certification, Gator Bio continues to demonstrate our competence and desire to effectively and efficiently provide a quality management system while continuously improving our products, services, and internal processes. We strive to consistently meet and exceed expectations of our customers.

PALO ALTO, Calif., June 1, 2022 /PRNewswire/ — Gator Bio, the next gen Biolayer Interferometry solutions company, has signed an agreement with I&L Biosystems GmbH, a distributor of innovative biomedical technology and products. The agreement will allow Gator Bio to expand rapidly its product offerings into the European Union, a key region for Gator’s growth strategy as it begins its global reach.

Dr. Hong Tan, CEO of Gator Bio, said, “I&L Biosystems has a history of bringing new and innovative technologies into market — as evidenced by its previous success in commercializing e.g., various multi-analyzer, protein purification devices, SPR instruments, and bioreactors, etc. We look forward to working with the I&L team to bring the Gator platform to users throughout the region, helping meet the demand for therapeutics development and manufacturing.”

“Gator BLI platform and a range of innovative biosensors are an important addition to I&L’s portfolio of protein characterization products, and we are very excited about the possibilities the Gator shall give our customers in characterizing antibodies, AAVs and small molecule drugs,” said Mr. Alexander M. Beljaars, CEO of I&L Biosystems GmbH. “Access to this next gen technology is key to the continued enablement of our biopharma and academia research customers across our geographies. We are very excited about helping research and manufacturing community with the novel applications in gene therapy, immune therapy and lipid nano particle development.”

The latest partnership of two companies builds on Gator Bio’s commitment to providing high-quality BLI platforms globally, recently demonstrated through a strategic partnership with BMS Korea (Bio Medical Sciences) to provide sales and services to biotherapeutics and gene therapy companies in Republic of Korea. To learn more, please visit www.gatorbio.com.

About Gator Bio, Inc.

Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio along with its sister company ET Healthcare are part of Access Medical Systems. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China. For more information, please visit www.gatorbio.com.

About I&L Biosystems

I&L Biosystems is a leading distributor of innovative scientific products with the headquarter in Königswinter, Germany. The company was founded in 1991 and has been growing steadily ever since. The focus of I&L is on sales and distribution of high-quality laboratory equipment to customers and researchers in the microbiology, cell biology and biotechnology markets in almost all European countries. High quality of the products, competent advice and fast service are the basis for a long-lasting relationship with our customers and partners in industry, research and development. More than 120 employees ensure that our customers throughout Europe receive excellent support for technical or application-related questions. Visit I&L Biosystems’ website for more information: www.il-biosystems.com.

Media and Investor Relations Contact:
Subodh Nimkar, Marketing Director
[email protected]
+1 650 575 0827
Website: http://www.gatorbio.com//
LinkedIn

PALO ALTO, Calif., Jan. 5, 2022 /PRNewswire/ — Drug makers, biotech companies, biologics developers and CROs will now have the much-needed 21 CFR Part11-compliant software for their GatorPrime and GatorPlus Biolayer Interferometry systems (BLI). The software announced today significantly enhances Gator Bio’s BLI solution for biologics development, which includes application-specific biosensors, Gator^® GatorOne Software and BLI systems.

“Our customers, in no uncertain terms, had told us that Gator Bio’s innovative and high-performance BLI solution would gain wider adoption in their biologics development with 21 CFR Part11 compliant software. Now it is made available. We were committed to delivering this much-needed solution, and with the release of Gator^®  Part11 Software we have delivered on our promise,” said CEO Dr. Hong Tan.

As further proof of our commitment to the Biopharma industry, we are also releasing an IQ/OQ service bundle for GatorPrime and GatorPlus system qualification that will further enhance confidence in data generated using these BLI systems. Both products are ready to ship.

About Gator Bio, Inc.

Gator Bio is a life-sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio and its sister company ET Healthcare are part of Access Medical Systems. Gator instruments and biosensors enable real-time analysis of biomolecular interactions, providing information on affinity, kinetics, concentration, epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates, providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China. For more information, please visit www.gatorbio.com.

Media and Investor Relations Contact:
Subodh Nimkar, Marketing Director
[email protected]
+1 650 575 0827